Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
Mais filtros

Base de dados
Ano de publicação
Tipo de documento
Intervalo de ano de publicação
1.
Mol Biol Rep ; 51(1): 256, 2024 Feb 01.
Artigo em Inglês | MEDLINE | ID: mdl-38302802

RESUMO

Introduction Multiple sclerosis (MS) is an autoimmune condition marked by inflammation and the loss of myelin in the central nervous system (CNS). The aim of this research was to understand how Thymoquinone regulate the molecular and cellular processes involved in controlling experimental autoimmune encephalomyelitis (EAE), which is an animal model often used to study MS. Methods Female C57BL/6 mice were split into different groups receiving different doses (low, medium, and high) of Thymoquinone simultaneously with EAE induction. Clinical scores and other measurements were observed daily throughout the 25-day post immunization. We assessed lymphocyte infiltration and demyelination in the spinal cord through histological staining, analyzed T-cell profiles using ELISA, and quantified the expression levels of transcription factors in the CNS using Real-time PCR. Results Thymoquinone prevented the development of EAE. Histological experiments revealed only a small degree of leukocyte infiltration into the CNS. Thymoquinone resulted in a notable reduction in the generation of IFN-γ, IL-17, and IL-6, while simultaneously increasing the production of IL-4, IL-10, and TGF-ß in Th2 and Treg cells. Results from Real-time PCR suggested Treatment with Thymoquinone decreased the expression of T-bet and ROR-γt while increasing the expression of Foxp3 and GATA3. Conclusion These findings showed that Thymoquinone could decrease both disease incidence and severity.


Assuntos
Benzoquinonas , Encefalomielite Autoimune Experimental , Esclerose Múltipla , Animais , Camundongos , Feminino , Citocinas/metabolismo , Camundongos Endogâmicos C57BL , Esclerose Múltipla/tratamento farmacológico , Anti-Inflamatórios/uso terapêutico
2.
Artigo em Inglês | MEDLINE | ID: mdl-32448107

RESUMO

OBJECTIVE: Pioglitazone (PG) is used to control high blood sugar in patients with type 2 diabetes mellitus. PG acts as a peroxisome proliferator-activated receptor γ agonist. In addition to the insulin-sensitizing effect, PG possesses anti-inflammatory effect. In this study, the protective effect of PG was evaluated against DNA damage induced by ionizing radiation in healthy human lymphocytes. METHODS: The microtubes containing human whole blood were treated with PG at various concentrations (1-50 µM) for three hours. Then, the blood samples were irradiated with X-ray. Lymphocytes were cultured for determining the frequency of micronuclei as a genotoxicity biomarker in binucleated lymphocytes. RESULTS: The mean percentage of micronuclei was significantly increased in human lymphocytes when exposed to IR, while it was decreased in lymphocytes pre-treated with PG. The maximum reduction in the frequency of micronuclei in irradiated lymphocytes was observed at 5 µM of PG treatment (48% decrease). CONCLUSION: The anti-inflammatory property suggested the mechanism action of PG for protecting human lymphocytes against genotoxicity induced by ionizing radiation.


Assuntos
Dano ao DNA/efeitos da radiação , Linfócitos/efeitos da radiação , Pioglitazona/farmacologia , Protetores contra Radiação/farmacologia , Raios X/efeitos adversos , Células Cultivadas , Dano ao DNA/efeitos dos fármacos , Humanos , Linfócitos/efeitos dos fármacos , Linfócitos/metabolismo , Testes para Micronúcleos
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA